![Steven M. Toler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Steven M.
Toler served as Vice President-Pharmaceutical Development at Bellicum Pharmaceuticals, Inc. from 2015 to 2018 and as Vice President-Clinical Pharmaceutical Sciences at Targacept, Inc. from 2013 to 2015.
He holds a doctorate degree from Mercer University and Chandler Medical Center, and an undergraduate degree from Georgia State University.
Anciens postes connus de Steven M. Toler
| Sociétés | Poste | Fin |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/05/2018 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Corporate Officer/Principal | 31/03/2015 |
Formation de Steven M. Toler
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
33
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Mercer University
 Mercer University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Discovers and develops nicotinic acetylcholine receptor based therapies | Health Technology |
Georgia State University
 Georgia State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chandler Medical Center
 Chandler Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
